[{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Denosumab","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"BeiGene","amount2":2.7999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":2.7999999999999998,"dosageForm":"Injection","sponsorNew":"BeiGene \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ Amgen"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eden Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ Not Applicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0.41999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"BeiGene \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ Amgen"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BeiGene \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ Amgen"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Not Applicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Oncology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Denosumab","moa":"Porcupine","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gedeon Richter \/ Hikma","highestDevelopmentStatusID":"10","companyTruncated":"Gedeon Richter \/ Hikma"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Not Applicable"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eden Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Eden Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lupin Ltd \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ DKSH"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alvotech \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Alvotech \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Henlius Biotech \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Organon"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alvotech \/ Not Applicable"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GlycoNex \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GlycoNex \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alvotech \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Denosumab

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AVT03 (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia & Xgeva. It is a RANK ligand inhibitor, which is being evaluated in phase 1 trials for bone loss in adult men.

                          Brand Name : AVT03

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 10, 2024

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : TVB-009P(denosumab) is a biosimilar candidate to Prolia, which is being developed for the high risk for fracture, such as osteoporosis in postmenopausal women.

                          Brand Name : TVB-009P

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 08, 2024

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : SPD8 (denosumab) is a biosimilar of Prolia and Xgeva, designed for use in postmenopausal women with osteoporosis. This medication is administered subcutaneously and functions as a RANKL inhibitor.

                          Brand Name : SPD8

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 19, 2024

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AVT03 (denosumab) is a biosimilar of Prolia and Xgeva, designed for use in postmenopausal women with osteoporosis. This medication is administered subcutaneously and functions as a RANKL inhibitor.

                          Brand Name : AVT03

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 02, 2024

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The partnership aims to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia®/Xgeva® (denosumab) medicines for osteoporosis and cancer-related bone loss respectively.

                          Brand Name : AVT03

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 11, 2024

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : STADA Arzneimittel

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : HLX14 (denosumab-biosimilar) is a fully human recombinant anti-RANKL monoclonal antibody, which is approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

                          Brand Name : HLX14

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 24, 2024

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Organon

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Wyost (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia & Xgeva. It is a RANK ligand inhibitor, which is approved for patients with bone metastases from solid tumors.

                          Brand Name : Wyost

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 22, 2024

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The collaboration aims for commercialization of AVT03 (denosumab), a monoclonal antibody and a biosimilar to Prolia & Xgeva. It is a RANK ligand inhibitor, being evaluated in bone loss in adult men.

                          Brand Name : AVT03

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 21, 2024

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I

                          Sponsor : Dr. Reddy\'s Laboratories

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Maiweijian (denosumab) is a fully human recombinant anti-RANKL monoclonal antibody, which is approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

                          Brand Name : Maiweijian

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 08, 2024

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Wyost (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia & Xgeva. It is a RANK ligand inhibitor, which is approved for patients with bone metastases from solid tumors.

                          Brand Name : Wyost

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 05, 2024

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank